Technology platform development for targeted plasma metabolites in human heart failure

Clinical Proteomics

Peipei Ping³  Mario Deng¹  Martin Cadeiras¹  CM Dominic Ng³  JH Howard Choi³  Anjum A Khan²  CY X’avia Chan³ 

[1] Ronald Reagan UCLA Medical Center, UCLA Medical Center, Los Angeles, CA 90095, USA;Thermo Fisher Scientific, San Jose, CA 95134, USA;NHLBI Proteomics Center at UCLA, Departments of Physiology and Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA

关键词: Sample preparation;    Targeted human plasma metabolomics;    Heart disease;   

Others  :  1026343
DOI  :  10.1186/1559-0275-10-7

 received in 2013-03-22, accepted in 2013-06-07,  发布年份 2013

【 摘 要 】

Background

Heart failure is a multifactorial disease associated with staggeringly high morbidity and motility. Recently, alterations of multiple metabolites have been implicated in heart failure; however, the lack of an effective technology platform to assess these metabolites has limited our understanding on how they contribute to this disease phenotype. We have successfully developed a new workflow combining specific sample preparation with tandem mass spectrometry that enables us to extract most of the targeted metabolites. 19 metabolites were chosen ascribing to their biological relevance to heart failure, including extracellular matrix remodeling, inflammation, insulin resistance, renal dysfunction, and cardioprotection against ischemic injury.

Results

In this report, we systematically engineered, optimized and refined a protocol applicable to human plasma samples; this study contributes to the methodology development with respect to deproteinization, incubation, reconstitution, and detection with mass spectrometry. The deproteinization step was optimized with 20% methanol/ethanol at a plasma:solvent ratio of 1:3. Subsequently, an incubation step was implemented which remarkably enhanced the metabolite signals and the number of metabolite peaks detected by mass spectrometry in both positive and negative modes. With respect to the step of reconstitution, 0.1% formic acid was designated as the reconstitution solvent vs. 6.5 mM ammonium bicarbonate, based on the comparable number of metabolite peaks detected in both solvents, and yet the signal detected in the former was higher. By adapting this finalized protocol, we were able to retrieve 13 out of 19 targeted metabolites from human plasma.

Conclusions

We have successfully devised a simple albeit effective workflow for the targeted plasma metabolites relevant to human heart failure. This will be employed in tandem with high throughput liquid chromatography mass spectrometry platform to validate and characterize these potential metabolic biomarkers for diagnostic and therapeutic development of heart failure patients.

【 授权许可】

   
2013 Chan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ: Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011, 123:933-944.
• [2]Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND, Roger VL: Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol 2009, 54:1695-1702.
• [3]Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS: Long-term trends in the incidence of and survival with heart failure. N Eng J Med 2002, 347:1397-1402.
• [4]Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ: Trends in heart failure incidence and survival in a community-based population. JAMA 2004, 292:344-350.
• [5]Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ: Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898-904.
• [6]Cotran RS, Kumar V, Robbins SL: Robbins’ Pathologic Basis of Disease. 4th edition. Philadelphia, PA: WB Saunders; 1989.
• [7]Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, Anversa P: Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994, 89:151-163.
• [8]Bing OH, Matsushita S, Fanburg BL, Levine HJ: Mechanical properties of rat cardiac muscle during experimental hypertrophy. Circ Res 1971, 28:234-245.
• [9]Averill DB, Ferrario CM, Tarazi RC, Sen S, Bajbus R: Cardiac performance in rats with renal hypertension. Circ Res 1976, 38:280-288.
• [10]Doering CW, Jalil JE, Janicki JS, Pick R, Aghili S, Abrahams C, Weber KT: Collagen network remodelling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc Res 1988, 22:686-695.
• [11]Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT: Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989, 64:1041-1050.
• [12]Weber KT, Brilla CG, Janicki JS: Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993, 27:341-348.
• [13]Dixon IM, Ju H, Jassal DS, Peterson DJ: Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Mol Cell Biochem 1996, 165:31-45.
• [14]Drexler H, Coats AJ: Explaining fatigue in congestive heart failure. Annu Rev Med 1996, 47:241-256.
• [15]Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD: Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999, 353:1838-1842.
• [16]Dzeja PP, Redfield MM, Burnett JC, Terzic A: Failing energetics in failing hearts. Curr Cardiol Rep 2000, 2:212-217.
• [17]Ashrafian H: Cardiac energetics in congestive heart failure. Circulation 2002, 105:e44-e45.
• [18]Ingwall JS, Weiss RG: Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004, 95:135-145.
• [19]Lower R: Tractatus de Corde: De Motu & Colore Sagnuinus et Chyli in Eum Tranfitu. 1st edition. London, UK: Jacobi Alleftry; 1669.
• [20]Yndestad A, Holm AM, Muller F, Simonsen S, Froland SS, Gullestad L, Aukrust P: Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003, 60:141-146.
• [21]Conraads VM, Bosmans JM, Schuerwegh AJ, Goovaerts I, De Clerck LS, Stevens WJ, Bridts CH, Vrints CJ: Intracellular monocyte cytokine production and CD 14 expression are up-regulated in severe vs mild chronic heart failure. J Heart Lung Transplant 2005, 24:854-859.
• [22]Oliver SG, Winson MK, Kell DB, Baganz F: Systematic functional analysis of the yeast genome. Trends Biotechnol 1998, 16:373-378.
• [23]Tweeddale H, Notley-McRobb L, Ferenci T: Effect of slow growth on metabolism of Escherichia coli, as revealed by global metabolite pool ("metabolome") analysis. J Bacteriol 1998, 180:5109-5116.
• [24]Nicholson JK, Lindon JC, Holmes E: 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189.
• [25]Fiehn O, Kopka J, Dormann P, Altmann T, Trethewey RN, Willmitzer L: Metabolite profiling for plant functional genomics. Nat Biotechnol 2000, 18:1157-1161.
• [26]Lewis GD, Gerszten RE: Toward metabolomic signatures of cardiovascular disease. Circ Cardiovasc Genet 2010, 3:119-121.
• [27]Waterman CL, Kian-Kai C, Griffin JL: Metabolomic strategies to study lipotoxicity in cardiovascular disease. Biochim Biophys Acta 1801, 2010:230-234.
• [28]Griffin JL, Atherton H, Shockcor J, Atzori L: Metabolomics as a tool for cardiac research. Nat Rev Cardiol 2011, 8:630-643.
• [29]Rhee EP, Gerszten RE: Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012, 58:139-147.
• [30]Senn T, Hazen SL, Tang WH: Translating metabolomics to cardiovascular biomarkers. Prog Cardiovasc Dis 2012, 55:70-76.
• [31]Turer AT: Using metabolomics to assess myocardial metabolism and energetics in heart failure. J Mol Cell Cardiol 2013, 55:12-18.
• [32]Ellis DI, Dunn WB, Griffin JL, Allwood JW, Goodacre R: Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 2007, 8:1243-1266.
• [33]Kaddurah-Daouk R, Kristal BS, Weinshilboum RM: Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 2008, 48:653-683.
• [34]Goonewardena SN, Prevette LE, Desai AA: Metabolomics and atherosclerosis. Curr Atheroscler Rep 2010, 12:267-272.
• [35]Mayr M, Liem D, Zhang J, Li X, Avliyakulov NK, Yang JI, Young G, Vondriska TM, Ladroue C, Madhu B, Griffiths JR, Gomes A, Xu Q, Ping P: Proteomic and metabolomic analysis of cardioprotection: Interplay between protein kinase C epsilon and delta in regulating glucose metabolism of murine hearts. J Mol Cell Cardiol 2009, 46:268-277.
• [36]Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, Brown M, Knowles JD, Halsall A, Haselden JN, Nicholls AW, Wilson ID, Kell DB, Goodacre R, Human Serum Metabolome C: Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 2011, 6:1060-1083.
• [37]Gilstrap LG, Wang TJ: Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem 2012, 58:72-82.
• [38]Vallejo M, Garcia A, Tunon J, Garcia-Martinez D, Angulo S, Martin-Ventura JL, Blanco-Colio LM, Almeida P, Egido J, Barbas C: Plasma fingerprinting with GC-MS in acute coronary syndrome. Anal Bioanal Chem 2009, 394:1517-1524.
• [39]Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R, Berriz GF, Roth FP, Gerszten RE: Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005, 112:3868-3875.
• [40]Dunn WB, Broadhurst DI, Deepak SM, Buch MH, McDowell G, Spasic I, Ellis DI, Brooks N, Kell DB, Neyses L: Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate. Metabolomics 2007, 3:413-426.
• [41]Lewis GD, Wei R, Liu E, Yang E, Shi X, Martinovic M, Farrell L, Asnani A, Cyrille M, Ramanathan A, Shaham O, Berriz G, Lowry PA, Palacios IF, Tasan M, Roth FP, Min J, Baumgartner C, Keshishian H, Addona T, Mootha VK, Rosenzweig A, Carr SA, Fifer MA, Sabatine MS, Gerszten RE: Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 2008, 118:3503-3512.
• [42]Alexander D, Lombardi R, Rodriguez G, Mitchell MM, Marian AJ: Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. Eur J Clin Invest 2011, 41:527-538.
• [43]Teul J, Ruperez FJ, Garcia A, Vaysse J, Balayssac S, Gilard V, Malet-Martino M, Martin-Ventura JL, Blanco-Colio LM, Tunon J, Egido J, Barbas C: Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and 1H NMR fingerprints. J Proteome Res 2009, 8:5580-5589.
• [44]Yap IK, Brown IJ, Chan Q, Wijeyesekera A, Garcia-Perez I, Bictash M, Loo RL, Chadeau-Hyam M, Ebbels T, De Iorio M, Maibaum E, Zhao L, Kesteloot H, Daviglus ML, Stamler J, Nicholson JK, Elliott P, Holmes E: Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease: INTERMAP study. J Proteome Res 2010, 9:6647-6654.
• [45]Tang WH, Wang Z, Cho L, Brennan DM, Hazen SL: Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol 2009, 53:2061-2067.
• [46]Want EJ, O'Maille G, Smith CA, Brandon TR, Uritboonthai W, Qin C, Trauger SA, Siuzdak G: Solvent-dependent metabolite distribution, clustering, and protein extraction for serum profiling with mass spectrometry. Anal Chem 2006, 78:743-752.
• [47]Zelena E, Dunn WB, Broadhurst D, Francis-McIntyre S, Carroll KM, Begley P, O'Hagan S, Knowles JD, Halsall A, Consortium H, Wilson ID, Kell DB: Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Anal Chem 2009, 81:1357-1364.
• [48]Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E: Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009, 81:6656-6667.
• [49]Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, Djoumbou Y, Mandal R, Aziat F, Dong E, Bouatra S, Sinelnikov I, Arndt D, Xia J, Liu P, Yallou F, Bjorndahl T, Perez-Pineiro R, Eisner R, Allen F, Neveu V, Greiner R, Scalbert A: HMDB 3.0--The Human Metabolome Database in 2013. Nucleic Acids Res 2013, 41:D801-D807.